Efficacy of agonists thrombopoetin receptor: romiplostim, eltrombopag in patients with recurrent primary immune thrombocytopenia

Автор: Kontievsky I. N., Golenkov A. K.

Журнал: Вестник гематологии @bulletin-of-hematology

Рубрика: Оригинальные статьи

Статья в выпуске: 4 т.15, 2019 года.

Бесплатный доступ

Background. Actuality relevanceof the study performed is due to the need toobtain new information about pharmaceuticaldrugs: Romiplostim, Eltrombopag that are thethrombopoietin agonists used in the severe formsof recurrent primary immune thrombocytopeniain actual clinical practice. Aim. To establish the cause-and-effect relationsbetween the administration of pharmaceuticaldrugs from the group of thrombopoietin receptoragonists (Romiplostim, Eltrombopag) and anincrease in the number of platelets in a non-selective group of patients one year later in thecourse of treatment. Materials and methods. The prospective cohort study included 87 patients aged 18 andolder with the primary immune thrombocytopenia and the backset after previous therapy, whoreceived treatment with Romiplostim andEltrombopag. The pharmaceutical drugs wereprescribed according to the following schemes:Eltrombopag 50 mg daily per os; Romiplostim 1pg/kg subcutaneously once a week. Evaluation ofthe treatment efficacy was performed in accordancewith the recommendations of the Russian ExpertCouncil. The paired Student t-test was studied toassess the hematological response in two groups ofpatients based on the applied stastica 10.0 softwarepackages. The quantitative data are presented inthe form of a median (Me) of the minimum and maximum values. The patient distribution in groupsfor treatment with Eltrombopag or Romiplostimwas performed without randomization. Results. All patients provided a response to thetherapy with Romiplostim and Eltrombopag. Inthe group treated with Romiplostim, all patientsdemonstrated the clinical and hematological effect. In the group of patients treated with Eltrombopag consisting of 59 people, the significantincrease in the level of platelet count from 47.4 (42-53 х 10*9/L) to 151 (133-170 х 10*9/L) (p function show_eabstract() { $('#eabstract1').hide(); $('#eabstract2').show(); $('#eabstract_expand').hide(); }

Еще

Короткий адрес: https://sciup.org/170172536

IDR: 170172536

Статья научная